There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib and venetoclax. In this video, Susan OBrien, MD, of the University of California, Irvine, CA, discusses the indications and reasoning for which to use, switching between them and sequencing. Prof. OBrien also covers combining these agents with one other and antibodies, in addition to resistance. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations
